AbbVie to Acquire Aliada Therapeutics for $1.4 Billion in Cash-January 2024-www.financetom.com

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion in Cash

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion in Cash

Nov 3, 2024 12:29 PM

08:14 AM EDT, 10/28/2024 (MT Newswires) -- AbbVie ( ABBV ) said Monday it has reached a definitive agreement to acquire Aliada Therapeutics, a biotechnology company, for $1.4 billion in cash.

The deal is expected to close in Q4, subject to regulatory approvals and other customary closing conditions.

Price: 187.99, Change: +0.14, Percent Change: +0.07

Previous page： Best Buy's Improving Outlook Largely Due to Gains During First Half of Fiscal Year, Wedbush Says Next page： Oracle Unusual Options Activity

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Best Buy's Improving Outlook Largely Due to Gains During First Half of Fiscal Year, Wedbush Says

Aug 31, 2024

12:16 PM EDT, 08/29/2024 (MT Newswires) -- Best Buy ( BBY ) performed better than expected during the first half of its fiscal 2025, with the retailer on Thursday reporting sales and adjusted earnings for its Q2 ended Aug. 3 that exceeded Wall Street forecasts, Wedbush said. Q2 comparable store sales were down 2.3%, Wedbush said, versus its estimate for...

Oracle Unusual Options Activity

Aug 31, 2024

Deep-pocketed investors have adopted a bearish approach towards Oracle , and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ORCL usually suggests something big is about to happen. We gleaned this information from our observations today...

Okta Posts Fiscal Q2 Beat; Macro Headwinds Still Weighing on Expansion Activity, Oppenheimer Says

Aug 31, 2024

12:19 PM EDT, 08/29/2024 (MT Newswires) -- Okta ( OKTA ) reported better-than-expected Q2 results but macro headwinds continue to weigh on spending and expansion activity, Oppenheimer said in a note emailed Thursday. Okta's ( OKTA ) Q2 revenue of $646 million and non-GAAP earnings of $0.72 per share both exceeded consensus estimates of $632.6 million and $0.61, respectively, according...

--Street Color: Salesforce President, CFO Amy Weaver Stepping Down

Aug 31, 2024

12:18 PM EDT, 08/29/2024 (MT Newswires) -- Price: 261.00, Change: +2.10, Percent Change: +0.81 ...